0
Skip to Content
BLOODPAC
BLOODPAC
About
Our Story
Our Team
Our Community
Annual Reports & Financials
Contact Us
Approach
How We Work
Reimbursement & Policy
Public Comments
Collaborative Studies
Data
BLOODPAC Portal
Impact
BLOODPAC Publications
Data Elements
Frameworks & Standards
Member Publications
BLOODPAC Events
Resources
BLOODPAC Governance
Insights
Videos
MEMBER LOGIN
BLOODPAC
BLOODPAC
About
Our Story
Our Team
Our Community
Annual Reports & Financials
Contact Us
Approach
How We Work
Reimbursement & Policy
Public Comments
Collaborative Studies
Data
BLOODPAC Portal
Impact
BLOODPAC Publications
Data Elements
Frameworks & Standards
Member Publications
BLOODPAC Events
Resources
BLOODPAC Governance
Insights
Videos
MEMBER LOGIN
Folder: About
Back
Our Story
Our Team
Our Community
Annual Reports & Financials
Contact Us
Folder: Approach
Back
How We Work
Reimbursement & Policy
Public Comments
Collaborative Studies
Folder: Data
Back
BLOODPAC Portal
Folder: Impact
Back
BLOODPAC Publications
Data Elements
Frameworks & Standards
Member Publications
BLOODPAC Events
Folder: Resources
Back
BLOODPAC Governance
Insights
Videos
MEMBER LOGIN
Understanding Molecular Residual Disease (MRD) in Solid Tumors
Liquid Biopsy Technology Guest User 3/13/23 Liquid Biopsy Technology Guest User 3/13/23

Understanding Molecular Residual Disease (MRD) in Solid Tumors

Read More
Understanding Tumor Mutational Burden (TMB)
Liquid Biopsy Technology Guest User 3/7/23 Liquid Biopsy Technology Guest User 3/7/23

Understanding Tumor Mutational Burden (TMB)

Read More
Contrived Materials in Liquid Biopsy Assay Development
Liquid Biopsy Technology Guest User 2/27/23 Liquid Biopsy Technology Guest User 2/27/23

Contrived Materials in Liquid Biopsy Assay Development

Read More

ABOUT

BLOODPAC is a consortium managed by the Center for Computational Science Research, Inc. (CCSR), which is an Illinois based 501 (c)(3) not-for-profit corporation. Our mission is to accelerate the development, validation, and accessibility of liquid biopsy assays to improve outcomes for patients with cancer. To do so, we lead a pre-competitive collaborative infrastructure that enables the sharing of information and building of consensus among stakeholders in industry, academia, regulatory bodies, payers, and government agencies.